RPG Life Sciences eyes acquisitions amid strong growth across segments

 RPG Life Sciences eyes acquisitions amid strong growth across segments

  • RPG Life Sciences is actively exploring acquisitions in both the formulations and active pharmaceutical ingredients (API) segments, says Managing Director Yugal Sikri.

  • The recent monetisation of land in Thane, near Mumbai, has strengthened the company’s position, leaving RPG Life Sciences with a cash surplus of over ₹200 crore after clearing its debt over the past five years. 
  • This surplus is now driving the company’s acquisition ambitions, Sikri said.
  • RPG Life Sciences operates in three main segments: domestic formulations, international formulations, and APIs.
  • Domestic formulations contribute about 66% of revenue, international formulations 19%, and APIs 15%, and all three segments are growing in double-digits
  • RPG Life Sciences: An Integrated Pharmaceutical Company APIs to Formulations; R&D to Manufacturing to Marketing
  • RPG Life Sciences, part of RPG Enterprises, is an integrated research based pharmaceutical Company operating in the domestic and international markets in the branded formulations, global generics and synthetic APIs space. 
  • Upticking Growth Trajectory 
  • Bold Move 1 :  Galvanizing Organization to an “Inspiring Purpose”: Framing and embedding in the organisation
  • Bold Move 2 :“Small Brands” to Building “Mega Brand of 100 cr +; future 500 cr OTC”: Naprosyn 
  • Bold Move 3 “Small Product” to Building “Mega Rx Portfolio of 100 cr +; Potential 200 cr” : Immunosuppressants 
  • Bold Move 4 “Small API” segment to Building “Formidable API Business”: Manthan 
  • Bold Move 5 Predominant “Domestic Play” to “Expanded Global Play” : Capex infusion ~140 cr 
  • Bold Move 6 “Operations” Focus to “Sustainable Operations” Focus: ESG    

Comments

Popular posts from this blog

Confidence Petroleum Forays into Hydrogen Cylinder Manufacturing

RSI Indicator for finding good value stocks?

Poonawalla Fincorp: I love stocks at 52L